Cortisone versus prolotherapy shots

Dr. Fred G. Arnold

Cortisone versus prolotherapy shots

Many people are confused about whether to use cortisone prolotherapy for treating painful joint conditions. It must be understood that cortisone prolotherapy are not the same treatment, the effects of each are dramatically different.

Cortisone, like prednisone, is a corticosteroid has numerous adverse harmful side effects on bone, joint soft tissue healing. On the other hand, prolotherapy is a safe recommended treatment for painful musculoskeletal conditions.

Prolotherapy strengthens bones, tendon-bone attachments muscles, strengthens rebuilds ligament tissue. Cortisone does not. Cortisone leads to progressive, harmful arthritic changes, suppresses the immune system, inhibits growth hormone inactivates vitamin D. Prolotherapy does not.

Cortisone shots can permanently damage bones, ligaments, muscles, cartilage tendons, which results in a weakening of the joint, progressing to degenerative joint disease osteoarthritis, osteoporosis, fractures muscle weakness. The joint becomes structurally weakened, which increases the pain, the need for more cortisone shots perhaps eventually surgery.

Many orthopedic physicians doctors treat musculoskeletal sports injuries with cortisone injections as a “quick fix” for pain relief. The unsuspecting athlete returns to the playing field thinking his condition is cured, when it is actually weakened by the cortisone injection.

Many athletes overstress their weakened joints, causing permanent damage that can lead to a chronic use of pain medications. Cortisone also can cause tendon rupture, particularly of the Achilles tendon. Prolotherapy is a proven orthopedic treatment to reduce pain strengthen weak joints, without the negative side effects of cortisone.

Fred G. Arnold, D.C., N.M.D., specializes in prolotherapy/pain rehabilitation services. He is one of the few physicians in the nation with both naturopathic chiropractic degrees. or

Reprinted from AzNetNews, Volume 31, Number 3, June/July 2012.

Found this helpful? Share it with someone who needs it.